Xenon Pharmaceuticals Inc. Net Income (Loss) Attributable to Parent in USD from 2012 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Xenon Pharmaceuticals Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2012 to Q3 2025.
  • Xenon Pharmaceuticals Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2025 was -$90.9M, a 44.8% decline year-over-year.
  • Xenon Pharmaceuticals Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2025 was -$306M, a 43.6% decline year-over-year.
  • Xenon Pharmaceuticals Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$234M, a 28.5% decline from 2023.
  • Xenon Pharmaceuticals Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$182M, a 45.5% decline from 2022.
  • Xenon Pharmaceuticals Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$125M, a 58.9% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)

Xenon Pharmaceuticals Inc. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$306M -$90.9M -$28.1M -44.8% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-03
Q2 2025 -$278M -$84.7M -$26.8M -46.2% Apr 1, 2025 Jun 30, 2025 10-Q 2025-11-03
Q1 2025 -$251M -$65M -$17.1M -35.7% Jan 1, 2025 Mar 31, 2025 10-Q 2025-11-03
Q4 2024 -$234M -$65.7M -$20.9M -46.8% Oct 1, 2024 Dec 31, 2024 10-K 2025-02-27
Q3 2024 -$213M -$62.8M -$14.3M -29.6% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-03
Q2 2024 -$199M -$57.9M -$10.5M -22% Apr 1, 2024 Jun 30, 2024 10-Q 2025-11-03
Q1 2024 -$189M -$47.9M -$6.2M -14.9% Jan 1, 2024 Mar 31, 2024 10-Q 2025-11-03
Q4 2023 -$182M -$44.7M -$7.35M -19.7% Oct 1, 2023 Dec 31, 2023 10-K 2025-02-27
Q3 2023 -$175M -$48.5M -$11.3M -30.5% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 -$164M -$47.5M -$16.3M -52.3% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-12
Q1 2023 -$147M -$41.7M -$22.1M -112% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-12
Q4 2022 -$125M -$37.4M -$11.8M -46.3% Oct 1, 2022 Dec 31, 2022 10-K 2025-02-27
Q3 2022 -$114M -$37.2M -$21.7M -141% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 -$91.8M -$31.2M -$9.05M -40.9% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-08
Q1 2022 -$82.8M -$19.7M -$3.91M -24.8% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-08
Q4 2021 -$78.9M -$25.6M -$13.2M -107% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-29
Q3 2021 -$65.6M -$15.4M -$6.59M -74.4% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 -$59.1M -$22.1M -$21.9M -12534% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-08
Q1 2021 -$37.1M -$15.8M -$8.28M -111% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-08
Q4 2020 -$28.8M -$12.3M -$947K -8.33% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-01
Q3 2020 -$27.9M -$8.86M +$16K +0.18% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$27.9M -$175K +$9.83M +98.3% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-10
Q1 2020 -$37.7M -$7.48M +$3.86M +34% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-10
Q4 2019 -$41.6M -$11.4M -$2.82M -32.9% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-01
Q3 2019 -$38.8M -$8.87M +$5.51M +38.3% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$44.3M -$10M -$2.21M -28.3% Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-05
Q1 2019 -$42.1M -$11.3M -$7.59M -202% Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-05
Q4 2018 -$34.5M -$8.56M -$493K -6.11% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-09
Q3 2018 -$34M -$14.4M -$6.64M -85.8% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-05
Q2 2018 -$27.4M -$7.8M -$421K -5.71% Apr 1, 2018 Jun 30, 2018 10-Q 2019-11-05
Q1 2018 -$26.9M -$3.76M +$3.76M +50% Jan 1, 2018 Mar 31, 2018 10-Q 2019-11-05
Q4 2017 -$30.7M -$8.07M -$2.06M -34.3% Oct 1, 2017 Dec 31, 2017 10-K 2018-03-07
Q3 2017 -$28.6M -$7.74M -$28K -0.36% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-06
Q2 2017 -$28.6M -$7.38M -$1.36M -22.7% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-07
Q1 2017 -$27.3M -$7.52M -$4.25M -130% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-08
Q4 2016 -$23M -$6M -$2.07M -52.5% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-07
Q3 2016 -$20.9M -$7.71M -$3.89M -102% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-07
Q2 2016 -$17M -$6.02M -$7.18M -615% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-07
Q1 2016 -$9.86M -$3.26M +$5.89M +64.4% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-07
Q4 2015 -$15.8M -$3.94M -$5.16M -422% Oct 1, 2015 Dec 31, 2015 10-K 2017-03-08
Q3 2015 -$10.6M -$3.83M -$13M -142% Jul 1, 2015 Sep 30, 2015 10-K 2017-03-08
Q2 2015 $2.43M $1.17M -$62K -5.04% Apr 1, 2015 Jun 30, 2015 10-K 2017-03-08
Q1 2015 $2.49M -$9.16M -$10.5M -767% Jan 1, 2015 Mar 31, 2015 10-K 2017-03-08
Q4 2014 $13M $1.22M Oct 1, 2014 Dec 31, 2014 10-K 2017-03-08
Q3 2014 $9.19M +$2.81M +44.1% Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-10
Q2 2014 $1.23M Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-13
Q1 2014 $1.37M Jan 1, 2014 Mar 31, 2014 10-Q/A 2015-08-13
Q3 2013 $6.38M Jul 1, 2013 Sep 30, 2013 10-Q 2014-12-15

Xenon Pharmaceuticals Inc. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$234M -$51.9M -28.5% Jan 1, 2024 Dec 31, 2024 10-K 2025-02-27
2023 -$182M -$57M -45.5% Jan 1, 2023 Dec 31, 2023 10-K 2025-02-27
2022 -$125M -$46.5M -58.9% Jan 1, 2022 Dec 31, 2022 10-K 2025-02-27
2021 -$78.9M -$50M -174% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-29
2020 -$28.8M +$12.8M +30.7% Jan 1, 2020 Dec 31, 2020 10-K 2023-03-01
2019 -$41.6M -$7.1M -20.6% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-01
2018 -$34.5M -$3.79M -12.4% Jan 1, 2018 Dec 31, 2018 10-K 2020-03-09
2017 -$30.7M -$7.71M -33.5% Jan 1, 2017 Dec 31, 2017 10-K 2019-03-06
2016 -$23M -$7.25M -46% Jan 1, 2016 Dec 31, 2016 10-K 2018-03-07
2015 -$15.8M -$28.8M -221% Jan 1, 2015 Dec 31, 2015 10-K 2018-03-07
2014 $13M +$986K +8.2% Jan 1, 2014 Dec 31, 2014 10-K 2017-03-08
2013 $12M +$16.3M Jan 1, 2013 Dec 31, 2013 10-K 2016-03-08
2012 -$4.3M Jan 1, 2012 Dec 31, 2012 10-K 2015-03-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.